Lyfegen Funding: How Much Did They Raise & Key Investors

How Much Did Lyfegen Raise?
Funding & Key Investors

Lyfegen, a Basel-based innovator in healthcare rebate management, has successfully secured a major strategic investment, bringing its total capital accumulation to $13.6M. This latest infusion of $5.6M underscores the company's pivotal role in digitizing complex drug pricing agreements for global health stakeholders. By streamlining the administrative overhead associated with pharmaceutical rebates, Lyfegen continues to solidify its position as a critical infrastructure provider for governments, insurers, and hospital payers worldwide.

The company's growth trajectory, marked by consistent backing from specialized healthcare and deep-tech investors, reflects a broader market shift toward data-driven financial transparency in the life sciences sector. As Lyfegen scales its operations across Europe, North America, and the Middle East, this recent financing round serves as a catalyst for further technological expansion and market penetration.

What is Lyfegen?

Lyfegen

Software

Financial Software

Healthcare Software

Founded in 2018, Lyfegen operates as an independent software provider specializing in the automation and optimization of drug pricing models. The company maintains the world's largest digital repository of innovative pricing agreements, providing clients with a robust simulator to model complex financial scenarios. By replacing manual, error-prone processes with a centralized digital platform, Lyfegen enables pharmaceutical companies and payers to achieve greater value and operational efficiency. Its market presence is defined by its ability to bridge the gap between complex regulatory requirements and financial performance, positioning it as a leader in the health-tech software vertical.

How much funding has Lyfegen raised?

Lyfegen has raised a total of $13.6M across 2 funding rounds:

2022

Series A

$8M

2024

Series A

$5.6M

Series A (2022): $8M with participation from aMoon and APEX Ventures

Series A (2024): $5.6M led by TX Ventures and aMoon

Key Investors in Lyfegen

aMoon

aMoon is a healthcare investment firm that partners with exceptional scientists and entrepreneurs to build companies focused on transforming healthcare through technology and biology.

APEX Ventures

APEX Ventures is a venture capital firm focused on deep-tech and medical innovations, aiming to build the next generation of world-leading companies.

TX Ventures

TX Ventures is a venture capital firm that focuses on early-stage investments in technology-driven companies, providing strategic support to foster long-term growth.

What's next for Lyfegen?

With this major enterprise-level funding, Lyfegen is well-positioned to accelerate its product roadmap and expand its global footprint. The strategic focus will likely center on enhancing its drug pricing simulator capabilities and deepening its integration with existing healthcare enterprise systems. As the demand for transparent, value-based healthcare pricing models grows, Lyfegen's ability to provide actionable insights will be instrumental in maintaining its competitive advantage. Future growth will likely involve scaling its sales and engineering teams to support the increasing complexity of international drug pricing agreements and the ongoing digital transformation of the global healthcare ecosystem.

See full Lyfegen company page

See More Financial Insights